1 November 2019 in Journal of Stomatology Oral and Maxillofacial Surgery
22 March 2022 in Lasers in Medical Science
1 September 2016 in Journal of Biomedical Optics
The purpose of this study was to evaluate the influences of helium–neon (He–Ne) and infrared (IR) lasers on the viability and proliferation rate of healthy and ovariectomy-induced osteoporotic (OVX) bone marrow mesenchymal stem cells (BMMSCs) in vitro. MSCs harvested from the BM of healthy and OVX rats were culture expanded. He–Ne and IR lasers were applied three times at energy densities of 0.6, 1.2, and for BMMSCs. BMMSCs viability and proliferation rate were evaluated by MTT assay on days 2, 4, 6, 14, and 21. The results showed that healthy BMMSCs responded optimally to using an IR laser after three times of laser radiation. Moreover, it was found that OVX-BMMSCs responded optimally to with He–Ne laser and one-time laser radiation. It is concluded that the low-level laser therapy (LLLT) effect depends on the physiological state of the BMMSCs, type of the laser, wavelength, and number of laser sessions. The biostimulation efficiency of LLLT also depends on the delivered energy density. LLLT can enhance the viability and proliferation rate of healthy and especially osteoporotic autologous BMMSCs, which could be very useful in regenerative medicine.
5 August 2013 in Journal of Nuclear Medicine Technology
186Re-1-hydroxyethylidene-1,1-diphosphonate (HEDP) is an attractive radiopharmaceutical for the treatment of bone pain arising from skeletal metastatic lesions. Currently, 186Re-HEDP is most commonly used in European countries. The aim of this study was to investigate the palliative efficacy and adverse effects of 186Re-HEDP in patients with different types of cancers and skeletal bone pain. Methods: Nineteen (8 male, 11 female) patients with various cancers (breast, prostate, renal cell carcinoma, colon, and neuroendocrine tumors) and painful bone metastases were included in the study. A dose of 1,480–3,330 MBq (40–90 mCi) of 186Re-HEDP was administered intravenously. The patients’ level of pain relief was assessed by the Visual Analog Scale for 8 wk after treatment and by a weekly blood cell count to evaluate for hematologic toxicity. Results: The overall response rate was 89.5%, and the mean pain score assessed by the Visual Analog Scale was reduced from 9.1 to 5.3 after 1 wk (P = 0.003). No adverse effects were reported by patients during intravenous administration or for up to 24 h after administration. A flare reaction was seen in 63.2% of patients, mainly during days 1–3, and lasted for 2–4 d. There was no significant correlation between the response to therapy and the flare reactions (P > 0.05). The nadir of platelet reduction occurred at the fourth or fifth week and led to platelet infusion in only 4 patients with a low baseline platelet count and diffuse skeletal metastases. Bone marrow suppression occurred in patients receiving higher doses, but no clinical problems were seen except in 2 patients who required packed cell transfusion similar to their prior transfusions. Conclusion: 186Re-HEDP is an effective radiopharmaceutical for the palliative treatment of metastatic bone pain and has minimal adverse effects.
1 April 2016 in Experimental Eye Research
1 November 2012 in Investigative Ophthalmology & Visual Science
Purpose. To investigate the short-term effects of extremely low frequency pulsed electromagnetic fields (ELF-PEMF) on the healing of alkaline-burned corneas in rabbits. Methods. Fifty-six alkaline-burned corneas from 56 rabbits were categorized into four groups: ELF-PEMF therapy with 2 mTesla (mT) intensity (ELF 2) for 30 minutes twice daily, ELF-PEMF therapy with 5 mT intensity (ELF 5) for 30 minutes twice daily, medical therapy (MT), and controls. Clinical examination together with digital photography of the corneas was performed on days 0, 2, 7, and 14. After euthanizing the rabbits, affected eyes were evaluated by way of histopathology. Finally the clinical and the histopathologic results of the four groups were compared. Results. None of the cases developed limbal ischemia, symblepharon formation, Descemetocele, or corneal perforation. Although the area of corneal defect in the ELF groups on day 2 was significantly less than the defects in MT, it was not notably different from those on days 7 and 14. Rate of significant corneal neovascularization on days 7 and 14 was not statistically different between the groups. The keratocyte loss in MT was significantly higher than in the ELF groups. Mild stromal scar formation was observed more frequently in ELF-PEMF groups than the control. Conclusions. Short-term ELF-PEMF therapy is a safe, noninvasive, and markedly effective method in healing alkaline-burned corneas, and its therapeutic results are comparable with those of MT.